Kymera Therapeutics
Kymera is a clinical stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system.
Org chart
Teams
View all
Discover similar companies
Quince Therapeutics
South San Francisco, United States · Post IPO Equity
Translate Bio
Lexington, United States · Post IPO Equity
Kura Oncology
San Diego, United States · Post IPO Debt
Celldex Therapeutics
Hampton, United States · Post IPO Equity
Magenta Therapeutics
Cambridge, United States · Post IPO Equity
Krystal Biotech
Pittsburgh, United States · Post IPO Equity
Bolt Biotherapeutics
Redwood City, United States · Post IPO Equity
Cidara Therapeutics
San Diego, United States · Post IPO Equity
Pulse Biosciences
Hayward, United States · Post IPO Equity
C4 Therapeutics
Cambridge, United States · Post IPO Equity
Axsome Therapeutics
New York, United States · Post IPO Equity
Stemline Therapeutics
New York, United States · Post IPO Equity
helps you hire
great candidates
It’s free to use - try it out today.